Latest Breaking News On - Susan levinson - Page 5 : comparemela.com

Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases April 08, 2021 18:58 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression.   Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 08, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced publication of new research entitled “ Inflammation Causes a Decrease in Gelsolin and Elevation of Interleukin-1β- Carrying Microparticles

Steven cordovanoSusan levinsonUniversity of maryland school medicineBioaegis therapeutics incAegis therapeutics incMaryland schoolGelsolin can preventDriven damageBlood vesselsChief executive officerBioaegis therapeuticsKey componentAegis therapeuticsசூசன் லெவின்சன்பல்கலைக்கழகம் ஆஃப் மேரிலாந்து பள்ளி மருந்துஆதரவு சிகிச்சை இன்க்